199.75 +0.60 (0.30%)
Pre-Market: 7:09AM EDT
|Bid||199.85 x 800|
|Ask||215.00 x 800|
|Day's Range||195.90 - 199.77|
|52 Week Range||115.40 - 201.30|
|PE Ratio (TTM)||90.32|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||179.20|
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals
Kitov Pharma (KTOV) gained as the FDA approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.
Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.
The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.
Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Drug pricing has been in the spotlight once again this month when President Donald Trump announced plans to lower prescription drug costs.
AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.
Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.
Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), with a market capitalization of US$4.12B, rarely draw their attention from the investingRead More...
Ligand Pharmaceuticals Incorporated (LGND) announced today the pricing of $650 million aggregate principal amount of 0.75% convertible senior notes due 2023 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Ligand has granted the initial purchasers a 13-day option to purchase up to an additional $100 million aggregate principal amount of the notes, solely to cover overallotments, if any. The notes will be unsecured senior obligations of Ligand.
NEW YORK, NY / ACCESSWIRE / May 17, 2018 / U.S. markets closed up on Wednesday, as investors appear to shrug off fears of increasing interest rate and bond yields. The Dow Jones Industrial Average gained ...
Ligand Pharmaceuticals Incorporated (LGND) announced today that it intends to offer, subject to market conditions and other factors, $650 million aggregate principal amount of convertible senior notes due 2023 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering of the notes, Ligand expects to grant the initial purchasers a 13-day option to purchase up to an additional $100 million aggregate principal amount of the notes, solely to cover overallotments, if any. Ligand intends to use a portion of the net proceeds from the offering of the notes to pay the cost of certain convertible note hedge transactions, taking into account the proceeds to Ligand of certain warrant transactions, each as described below, and to repurchase up to $50 million of shares of Ligand’s common stock from purchasers of notes in privately negotiated transactions, which could increase the market price of Ligand’s common stock prior to, concurrently with, or shortly after the pricing of the notes, and could result in a higher effective conversion price for the notes.